Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - Shuttle Pharmaceuticals, Inc.s106657_ex32-2.htm
EX-31.2 - EXHIBIT 31.2 - Shuttle Pharmaceuticals, Inc.s106657_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - Shuttle Pharmaceuticals, Inc.s106657_ex31-1.htm
10-Q - QUARTERLY REPORT - Shuttle Pharmaceuticals, Inc.s106657_10q.htm

   

Exhibit 32.1

  

CERTIFICATION OF CHIEF EXECUTIVE OFFICER  

PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED 

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

  

In connection with the Quarterly Report of Shuttle Pharmaceuticals, Inc., a Maryland corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anatoly Dritschilo, the Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

  

1.          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

  

2.          The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

Date: June 26, 2017 SHUTTLE PHARMACEUTICALS, INC.
     
  By: /s/ Anatoly Dritschilo
    Anatoly Dritschilo, Chief Executive Officer
    (Principal Executive Officer)